WO2023166346 - PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST
National phase entry:
Publication Number
WO/2023/166346
Publication Date
07.09.2023
International Application No.
PCT/IB2023/000120
International Filing Date
01.03.2023
Title **
[English]
PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST
[French]
PROCÉDÉ DE PRÉPARATION D'UN ANTAGONISTE DE RÉCEPTEUR EDG-2 CRISTALLIN
Applicants **
HORIZON THERAPEUTICS IRELAND DAC
Inventors
BILLEN, Denis
MARTIN, Bénédicte
O'MAHONY, Michelle
Priority Data
63/315,898
02.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4090 | |
| EPO | Filing, Examination, Granting | 54967 | |
| Japan | Filing, Examination, Granting | 3967 | |
| South Korea | Filing, Examination, Granting | 5395 | |
| USA | Filing, Examination, Granting | 16140 |
Total:
84,559
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are methods of making crystalline Form 1 of 2-(4-methoxy-3-(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid.[French]
L'invention concerne des procédé de préparation de la forme cristalline 1 de l'acide 2-(4-méthoxy-3-(3-méthylphénéthoxy)benzamido)-2,3-dihydro-1H-indène-2-carboxylique.